Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
RegulatoryapprovedDaraxonrasibRasonquePositive
AI Analysis
Summary
Daraxonrasib (Rasonque) has received FDA approval for metastatic pancreatic cancer, with Karmanos Cancer Institute now offering the treatment following its pivotal RASolute 302 clinical trial.
Clinical Trial Data
Outcome Details
FDA approval of Daraxonrasib (Rasonque) for metastatic pancreatic cancer
Importance:8/10
Sentiment:
0.70
FDA approvalpancreatic canceroncologyRASolute 302 trialnew treatment
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 31, 2026 10:05 AM